Clinical trials: Vincristine
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A…
- Conditions
- Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT05326516
- Testing
- Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- Soundtrack-E (NCT06564038)
- Testing
- Surovatamig, Prednisone (or equivalent), Rituximab
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 408 people
- Sponsor
- AstraZeneca
Multiple Myeloma, Myeloma
Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine how well newly diagnosed multiple myeloma patients respond to an experimental regimen of Vincristine, DOXIL (doxorubicin HCl liposome injection) and Dexamethasone (VDD) versus the…
- Conditions
- Multiple Myeloma, Myeloma, M-Protein, Myeloma Proteins
- Trial name
- NCT00344422
- Testing
- Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
- Volunteers
- 198 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Lymphoblastic Leukemia
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute…
- Trial name
- NCT02404220
- Testing
- Entospletinib, Vincristine, Dexamethasone
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Large B-cell Lymphoma
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
This is a study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) in participants aged 18 to < 80 years of age with previously untreated large B-cell…
- Trial name
- Soundtrack D3 (NCT07911553)
- Testing
- Surovatamig, Rituximab, Cyclophosphamide
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell…
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- EPCORE™ NHL-3 (NCT04542824)
- Testing
- Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- Where
- 15 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Genmab
Diffuse Large B-Cell Lymphoma
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, and…
- Trial name
- LOTIS-8 (NCT04974996)
- Testing
- Loncastuximab tesirine, Prednisone, Rituximab
- Where
- United States
- Sponsor
- ADC Therapeutics S.A.
Follicular Lymphoma
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.
- Trial name
- NCT07187960
- Testing
- TQB2825 Injection, Rituximab Injection
- Where
- 28 sites in China
- Volunteers
- 228 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Lymphoma
Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma
This study is a Phase I trial of Darinaparsin in combination with CHOP for the treatment of lymphoma. Eligible patients will not have had any previous anti-cancer treatment and will be eligible to receive CHOP alone.
- Trial name
- NCT01139359
- Testing
- darinaparsin, CHOP
- Sponsor
- Alaunos Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL)…
- Trial name
- NCT03384654
- Testing
- Daratumumab, Vincristine, Prednisone
- Where
- 53 sites in United States, Belgium and 8 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell…
- Conditions
- Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
- Trial name
- ECHELON-2 (NCT01777152)
- Testing
- brentuximab vedotin, doxorubicin, prednisone
- Where
- 144 sites in United States, Australia and 14 more
- Volunteers
- 452 people
- Sponsor
- Seagen Inc.
Sarcoma, Kaposi, HIV Infections
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered…
- Trial name
- NCT00002093
- Testing
- Daunorubicin (liposomal), Bleomycin sulfate, Vincristine sulfate
- Where
- 13 sites in United States
- Sponsor
- Nexstar Pharmaceuticals
Chemotherapy, Nerve Degeneration
Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs
The study hypothesis is that changes in serially obtained nerve conduction study data obtained every 3-4 weeks in cancer patients receiving chemotherapy can be used to predict the development of a clinically significant /…
- Conditions
- Chemotherapy, Nerve Degeneration, Nerve Conduction
- Trial name
- NCT01208545
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- NeuroMetrix, Inc.
Acute Lymphoblastic Leukemia (ALL)
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
The purpose of Phase 1b of this study is to: Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia…
- Trial name
- NCT02303821
- Testing
- Carfilzomib, Dexamethasone, Mitoxantrone
- Where
- 122 sites in United States, Argentina and 31 more
- Volunteers
- 141 people
- Sponsor
- Amgen
Advanced Hodgkin's Lymphoma
Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol
1. To observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for patients with advanced Hodgkin's lymphoma. 2.
- Trial name
- NCT02800447
- Testing
- Natulan, ABVD
- Volunteers
- 92 people
- Sponsor
- Lee's Pharmaceutical Limited
Diffuse Large B-Cell Lymphoma
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large…
- Trial name
- POLARIX (NCT03274492)
- Testing
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide
- Where
- 209 sites in United States, Australia and 20 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Mantle-Cell
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
The primary efficacy endpoint of this study is to determine the duration of response of the sequential administration of Iodine-131 Anti-B1 Antibody followed by six cycles of CHOP for patients with previously untreated Mantle…
- Trial name
- NCT00992992
- Testing
- Tositumomab and Iodine I 131 Tositumomab followed by CHOP
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-cell Lymphoma
Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma
This is a multicenter, double-blind, randomized study comparing the efficacy, pharmacokinetics (PK)/pharmacodynamics (PD), safety and immunogenicity profile of RTXM83 (rituximab biosimilar) vs reference rituximab (MabThera®)…
- Trial name
- NCT02268045
- Testing
- RTXM83, Mabthera
- Where
- 87 sites in Argentina, Brazil and 10 more
- Volunteers
- 272 people
- Sponsor
- mAbxience Research S.L.
Diffuse Large B-Cell Lymphoma, Unspecified Site
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus…
- Trial name
- NCT03650933
- Testing
- G-CHOP, R-CHOP
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Small-cell Lung Cancer
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer…
- Trial name
- ATLANTIS (NCT02566993)
- Testing
- Lurbinectedin (PM01183), Doxorubicin (DOX), Cyclophosphamide (CTX)
- Where
- 160 sites in United States, Argentina and 18 more
- Volunteers
- 613 people
- Sponsor
- PharmaMar